Regeneron Tests Weekly Praluent Dosing in New Cholesterol Study: What Investors Should Watch
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
The study A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Weekly Alirocumab in Adults With Hypercholesterolemia tests a new weekly schedule for Regeneron’s cholesterol drug. It aims to show if once‑a‑week dosing is safe, lowers bad cholesterol enough, and offers a more convenient option for high‑risk patients.
The intervention is alirocumab, a PCSK9 antibody sold as Praluent in the U.S. today. The trial compares several weekly doses of alirocumab to find the best balance of safety, LDL‑C reduction, and ease of use for adults with high cholesterol.
The study is an interventional Phase 2 trial with participants randomly placed into one of four dose groups. It uses an open‑label, parallel‑group design, so both doctors and patients know the dose given, and the main goal is treatment, not diagnosis or prevention.
The trial is listed as recruiting, with first submission on 12 March 2026, signaling that enrollment is underway or about to start. The latest update on 8 June 2026 shows the protocol is active and has been recently reviewed, though primary and final completion dates are not yet posted.
For investors, this update underscores Regeneron’s push to extend the lifecycle of Praluent and defend share in the cholesterol market against other PCSK9 and oral LDL‑lowering drugs. Positive data on a convenient weekly regimen could support modest upside for REGN, improve sentiment on its cardiovascular franchise, and slightly pressure competitors focused on similar high‑risk patients.
The study is currently ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
